Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
Status:
Terminated
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy, safety and recurrence rate of two
therapeutic strategies with ribavirin in patients with chronic hepatitis E and severe acute
hepatitis E: fixed duration of treatment for 12 weeks vs variable duration depending on the
viremia within 4 weeks of the start of treatment (12 vs 24 weeks).
The purpose of the study is also improve the safety of treatment with Ribavirin by optimizing
dose adjusted to renal function, plasma levels of drug and hemoglobin.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute